Dolastatin derivatives, their preparation and use
Patent Information
- Application Number
- MYPI1996002155
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1995-06-07
- Filing Date
- 1996-06-03
- Publication Date
- 1996-12-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Natural dolastatin peptides face challenges such as poor solubility in aqueous solvents and high costs for synthesis, limiting their potential in cancer treatment.
Development of novel dolastatin derivatives with improved therapeutic potential, featuring specific peptide structures and synthesis methods that enhance solubility and reduce production costs, allowing for more effective cancer treatment.
The new derivatives demonstrate enhanced resistance to enzymatic degradation and improved therapeutic efficacy for treating neoplastic diseases, with potential for more efficient and cost-effective cancer treatment compared to Dolastatin-15.
Abstract
Description
DOLASTATIN DERIVATIVES, THEIR PREPARATION AND USEDescriptionThe present ’invention relates to dolastatin derivatives, their preparation and use weil as to pharmaceutical compositions containing said derivatives.It is known that: peptides isolated from marine origin like Dolastatin-10 (US4,816, 444) and Dolastatin-15 (EP-A398558) show potent cell· growth inhibitory activity (cf.: Biochem. Pharmacology 40, no. 8,1859-64, 1990); J.Natl.Cancer Inst. 85,483-88, 1993 and references cited therein). Based upon interesting1results in experimental tumor systemsI in vivo, further preclinical evaluation of these naturalI product is currently under way in order to initiate clinical· studies in cancer patients. However, the natural products have disadvantages, such as poor solubility in aqueous solvents and costly building blocks needed for synthesis.WO 93 / 23424 describes derivatives of dolastatin having the formulaCO - A - a - (D)t - f£Ju- (F)v- (G)w- κ I whereR1is alkoxy; alkyl; cycloalkyl; alkylsulfonyl;fluofoaikyi; trifluoroacety; amidino; ureyl;piperidinosulfonyl; morpholinosulfonyl ;benzyloxycarbonyl; alkyloxycarbdnyl;t aminosulfonyl which may be substituted by ! ί alkyl; ihydroxy; aryisulfonyl which may be substituted by one or more substituentsR‘Rx-N-R2* ίD,E,F and GI independently selected from alkyl, -N (CH3)2, nitro,j halogen and CF3; benzyl which may be substituted by up to three substituents independently selected from alkyl, alkoxy, nitro,j halogen and CF3; or NR3R4where R3andR* may' each be either hydrogen or alkyl;ί ίι is hydrogen; alkyl; fluoroalkyl; cycloalkyl;I acyl; benzoyl which may both be substituted by up to three substituents independently selected from nitro, halogen, CF3, alkyl and alkoxy';together may be phthalimido, a 5-or 6membered heterocycle which may be iunsubstituted or substituted with one or more substituents independently selected from phenyl,· benzyl, alkyl·, N(CHa)2, nitro, thienyl, CONH2and COOEt !is a valyl, isoleucyl, leucy, allo-isoleucyl, α-aminoisobutanoyl, 3-tert-butylalanyl, 2I tert-butylglycyl, 3-cyclohexylalanyl, 2,4diamino'butanoyl, ornithyl, lysyl, 2ethyl'glycyl, 2-cyclohexylglycyl, norleucyl, ίnorvalyl or arginyl residue;II is a N-alkyl-valyl, -norvalyl, -leucyl, isoleucyl, 2-tert-butylglycyl, -3-tertbutylalanyl, -3-cyclohexylalanyl, phenylalanyl, or-2-cyclohexylglycyl residue;ι are independently selected from the group consisting of prolyl, hompo-prolyl,I10!, l· hydroxyprolyl·, thiazolidinyl-4-carbonyl, Iamino^entyl-1-carbonyl, valyl, 2-terti butylglycyl, isoleucyl, leucyl, 3cyclohexylalanyl, phenylalanyl, Nmethylphenylalanyl, tetrahydroisoquinolyl-2carbonyl, 3-thiazolylalanyl, 3-thienylalanyl,I histidy, 1-aminoindyl-1-carbonyl, 2,4diaminobutanoyl, arginyl, 3-pyridylalanyl·, 3tert-butylalanyl, 2-cyclohexylglycyl, lysyl, norvalyl, norleucyl and 3-naphtylalanyl residues >.kI i, ίis hydrogen, alkyl, cycloalkyl, -CH2cyclohexyl or arylalkylA and B together', F and G together, R^N-CHX-CO and A together, E and F together, either alone or in pairs, may be ί' where Y is hydrogen or lower alkyl; Z is hydrogen or lower ‘alkyl; n is 1, 2, or 3; V is oxygen or sulfur; M is hydrogen, lower alkyl, arylalkyl, cyclohexyl, or -CH^-cyclohexyl; Q is hydrogen; R is hydrogen or lower alkyl; or R and, Q may together form a bond; U is hydrogen, lower alkyl, phenyl, or cycloalkyl;I and W 'is hydrogen, lower alkyl or phenyl;t,u,v, and w are independently 0 or 1; and is hydroxy, alkoxy, phenoxy, benzyloxy or a substituted or unsubstituted amino moiety;provided that where Hu,v and w are 0, K is not a hydroxy, alkoxy, benzoxy or phenoxy moiety; and further provided that where t, u and v are O', K is not a hydroxy or alkoxy moiety;and the salts thereof 'with physiologically tolerated acids.iThe invention described herein provides novel peptides ίand derivatives thereof which offer improved therapeutic ίpotential for the treatment of neoplastic diseases as compared to Dolastatin-15. Furthermore, the compounds of this invention may be conveniently synthesized as described in detail below.Compounds of this invention include novel peptides of ]the formula I iVFr’N-CHX-CO-A-B-D-E- (F)t-K whereR1is methyl, ethyl·, or isopropyl;R:is hydrogen, methyl·, or ethyl;R^N-R2A jtogether may be a pyrrollidine ring;i iis a valyl, isoleucyl, leucyl, 2-tert-butylglycyl, 2-ethylglycyl, norleucyl or norvalyl residue;is a N-methyl-valyl, -leucyl, -isoleucyl, norvalyl, -norleucyl-2-tert-butylglycyl,-3-tertbutylalanyl; or -2-ethylglycyl residue;.is a 3,4-dejydroprolyl, 4-fluoroprolyl, 4,4di f luoroproply ,· azetidine-2-carbonyl, 3methylprolyl, 4-methylprolyl, or 5-methylproly1 residue; j iis a prolyl, homoprolyl, hydroxyprolyl or thiazolidind-4-carbonyl residue;i is a valyl, 2-tert-butylglycyl, isoleucyl, leucyl,I2-cyclohexylglycyl, norleucyl, norvalyl, )neopentylgl.ycyl, alanyl, β-alanyl, orI aminoisobutyroyl residue;II iI is alkyl (preferably C2_5) , cyclopropyl, or cyclopentyl;j is 0 or 1; and ίίI is C^-alkoxy, benzyloxy, -NH3; -NH-Cj.^-alkyl, NH-C (CH3)2CN,; -NH-C (CH3)2CCH, -NH-C (CH3)2C=CH2, -NHC (CH3)2CH2CH2o'h, -NH-C (CH3)2CH2OH , -NH-C3_g-cycloal ky 1, -NH- [ 3,3, 0)-bicyclooctyl, norephedryl, norpseudoephedryl, -NH-quinolyl, -NH-pyrazyl, -NHCH2-benzimidazolyl, -NH-adamantyl, -NH-CH2adamantyl, -NH-CH (CH3)-phenyl, -NH-C (CH3)2-phenyl,I10'-Ν (C^-alkoxy) -C^-alkyl, -N {C^-alkoxy) -CH,-phenylf-N (C^-alkoxy)-phenyl, -N(CH,)0Bzl, -NH-(CH2)Vphenyl (v=0,l,2, or 3), -NH-(CR,) m-naphthyl (m=0 or 1), -NH-(CH2) w-benzhydryl (w=0,l, or 2), -NHbiphenyl, ί-ΝΗ-pyridyl, -NH-CH2-pyridyl, -NH-CH2CH2-pyriidyl, -NH-benzothiazolyl, - N H benzoisothiazolyl, -NH-benzopyrazolyl, -NHbenzoxazolyl, -NH- (CH2) m-f luorenyl {m=0 or 1) , NH-pyrimidyl, -NH-(CH2)m-indanyl (m=0 or 1),-NH(CH2CH2O) y-CH3(y=0,1,3,4, or 5), -NH-(CH2CH2O) yCH2CH3(y=0,1,2,3,4, or 5), - (CH2CH2O) y-CH3(y=0, 1,2, 3 / 4, or 5} , - (CH2CH2O) y-CH2CH2CH3(y=0, 1,2,3,4, or' 5), -NCH3-NH-C6H5, -NCH3-NH-CH2-C6H5; or K isJ- ίOEt-N S = 0 / -\ / θ H.C H,CV— OEt-JO — NIfI.tl·I1iCompound of this invention also include the salts of 5 - the peptides with physiologically tolerated acids.J This invention also provides methods for preparing the : ί compounds of formula I, pharmaceutical compositions I containing such compounds together with a pharmaceuticallyfacceptable carrier and methods for using same for treatingJ cancer in mammals. ί.t Preferred are compounds of the formula I where the v substituents Ri, R2, A / B, D, Ε, X, F and t have the ' j following meanings ,Ri is methyl or, ethyl;f ί f R2 is hydrogen^ methyl, or ethyl;I r A is a valyl, ’isoleucyl, 2-tertr butylglycyl residue;j B is a N-methyi-valyl, -isoleucyl, i or -2-tert-butylglycyl residue;D is a 3,4-dehydroprolyl·, 4-fluoroprolyl,E azetidine-2-carbonyl, 3-methylprolyl, or 5-methyl-prolyl residue;jE is a prolyl,·homoprolyl, hydroxyprolyl or thiazolidine?4-carbonyl residue;[ i p is aD-valyl,: 2-tert-butylglycyl, D-isoleucyl, j D-leucyl, or,aminoisobutyroyl residue;I- ...I X,.. is -CH(CH3)2,j -C(CH3)3, or -CH(CH3)CH2CH3;it is 0 or 1; ί . 1 | 1' ! < ,. ,. . . <’ ί ' ί 'ί ' ί ! l· ί'Preferred meanings for K are:-OC(CH3)3, -NHCH3, -NHCH2CH3, -NH(CK2)2CHj, '-NH(CH2)3CH3, -NH(CH2)4CH3, -NK(CH2) 5:CH3, -NH(CH2)6CH3, -NK(CH2)7CH3 / -NHCH(CH3)2r-NHCH(CH3)CH2CH3, -NKCH(CH3)CH2CH2CH3, -NHCH(CH2CH3)2, -NH(CH2CH2CH3)2, -NHC(CH3)3,-nhch(ch2ch3)ch2ch2ch3,'; -nhch(ch3)CH(Ch3)2,-NHCH(CH2CH3)CH(CH3)2, -NHCH(CH3)C(CH3)3, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cy’clopentyl, -NH-cyclohexyl, -NH-cycloheptyl, -NH-cyclooctyl, -NH-bicyclo[3,3,0]octyl, -N(CH3)OCH3, -N(CH3)OCH2CH3, -N(CH3)OCH2CH2CH3, -N(CH3)OCH(CH3)2, -N(CH'2CH3)OCH3, -N[CH2CH3)OCH2CH3, -N(CH(CH3)2)OCH3, -N<CH3)OCH2C6Hs, -N ( och3) ch2-c6h5, -N(CH3)OC6H5, -NH-CH2-C^H5, -NH(CH2)2C6H5, -NH(CH2)3C6H5, -NHCH(CH3)C6H5, -NHC(CH3)2C€H5, -NHC(CH3)2CH2CH3,-NHC(CH3) (CH2CH3)2, -NHCH(CH3)CH(OH)C6H5, -NHCH2-cyclohexyl, -NH-CH2CF3, -NHCH(CH2F)2, -NHC(CH3)2CH2CH2OH, -NH(CH2CH2O)2CH2CH3, -NHC(CH3)2CH(CH3)2, -NHC(CH3)2CN,-NHC(CH3)2CCH, norephedryl, norpseudoephedryl,-NH-quinolyl, -NH-pyrazyl, -NH-adamantyl(2),-NH-adamantyl(1), -NH-CH2-adamantyl, -NH-CH2-naphthyl, -NH-benzhydryl, -NH-biphenyl, -NH-pyridyl, -NH-CH2-pyridyl, -NH-CH2-CH2-pyridyl, -NH-benzothiazolyl, -NH-benzoisothiazolyl, -NH-benzopyrazolyl, -NH-benzoxazolyl,-NH-fluorenyl, -NH-pyrimidyl, -NH-CH2-(4-methyl)thiazolyl(2), -NH-CH2-furanyl(2), -NH-CH2-thienyl(2), -NH-CH2-(5-methyl)thienyl(2), -NH-thiazolyl(2), -NH-isoxazolyl (3) , -NH-'( 3 - methyl) isoxazolyl (5),-NH-(3-methyl)isothiazolyl(5), -NH-(2-trifluormethyl)thiadiazolyl(S)-NHC(CH3)2OCH2,VJ-NH-(2 rcyclopropyl)thiadiazolyl(5 or K may be / -οVJH,ch3c — NH3CλkitThese examples illustrate but do not limit the scope of the ' present invention. i k !' , I· r The peptides of the formula I are composed of L-amino acids1but F may also be a Diamino acid.f' iThe new compounds may ibe present as salts with | physiologically tolerated acids such as: hydrochloric acid, citric acid, tartaric ;acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic ί acid, fumaric acid, malic acid, succinic acid, malonic ι acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic ί acid, oxalic acid, ascorbic acid and acetylglycine.15ίI The novel compounds can be prepared by known methods of , peptide chemistry. Thus, the peptides can be assembled j sequentially from amino acids or by linking suitable small j' peptide fragments. In the sequential assemblage, starting j at the C terminus the peptide chain is extended stepwise by t one amino acid each time. In fragment coupling it is . possible to link together fragments of different lengths, ί and the fragments in turn can be obtained by sequential j assemblage from amino acids or themselves by fragment1coupling. !Both in the sequential;assemblage and in the fragment j coupling it is necessary to link the units by forming anJ amide linkage. Enzymatic and chemical methods are suitable>for this. ίChemical methods for forming the amide linkage are described in detail by|Mueller, Methoden der organischen Chemie Vol. XV / 2, pp 1 !to 364, Thieme Verlag, Stuttgart, 1974; Stewart, Young, Solid Phase Peptide Synthesis, pp 31 to 34, 71 to 82, Pierce Chemical Company, Rockford, 1984; Bodanszky, Klausner, Ondetti, Peptide Synthesis, pp 85 to 128, John Wiley & Sons,I New York, 1976 and other standard works on peptide chemistry. Particular preference is given to the azide method, the symmetric and mixed anhydride method, in si,tu generated or preformed active esters., _the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents / activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC ),1-ethoxycarbonyl-2-ethoky-1,2-dihydroquinoline (EEDQ),1~ethy1 - 3 - (3 ~dimethylamincpropy1) carbodiimide hydrochloride (EDCI), n-propanephosphonic anhydride (PPA), N,N-bis(2-oxo13-oxazolldinyl)-amidophosphoryl chloride (3OP-C1), bromoI tris-pyrrolidinophosphonium hexafluorophosphate (PyBroD), ί diphenylphosphoryl azide (DPPA), Castro's reagent (BOP, ’ PyBop), O-benzotriazolyl-N,N,N', N1-tetramethyluronium salts [ (HBTU), O-Azabenzotriazolyl-Ν,Ν,Ν',N'-tetramethyluronium l salts (HATU), diethylpAosphoryl cyanide (DEPCN),t- 2,5 - diphenyl - 2 , 3-dihydro- 3 - oxo-4 - hydroxythiophene dioxide1(Steglich's reagent; HOTDO) and 1,1'-carbonyldiimidazole I (CDI). The coupling reagents can be employed alone or in i combination with additives such as N,N-dimethyl-4-aminof pyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), ίAzabenzotriazole (HOAt), N-hydroxy* succinimide (HOSu) or 2-hydroxypyridine.Whereas it is normally^possible to dispense with protective ! groups in enzymatic peptide synthesis, reversible I protection of reactive .'groups not involved in formation of . the amide linkage is necessary for both reactants in ► chemical synthesis. Three conventional protective group ( techniques are preferred for the chemical peptide synthesis: the benzyloxycarbonyl (Z), the t-butoxycarbonyl ' (Boc) and the 9-fluorenylmethoxycarbonyl (Fmoc) techniques.Identified in each case is the protective group on the I alpha-amino group of the chain-extending unit. A detailed review of amino-acid protective groups is given by Mueller, Methoden der organischen Chemie Vol. XV / 1, pp 20 to 906, Thieme Verlag, Stuttgart, 1974. The units employed for assembling the peptideichain can be reacted in solution, in h suspension or by a method similar to that described by ! Merrifield in J. Amer. ;Chem. Soc. 85 (1963) 2149.J Particularly preferred methods are those in which peptides f are assembled sequentially or by fragment coupling using » the Z, Boc or Fmoc protective group technique, ι One of the reactants ih the said Merrifield technique is ::being bonded to an insoluble polymeric support (also calledJ resin hereinafter). This typically entails the peptide ϊ being assembled sequentially on the polymeric support using [ the Boc or Fmoc protective group technique, the growing ' peptide chain being covalently bonded at the C terminus to ι the insoluble resin particles (cf. Fig. 1 and 2). ThisL“procedure makes it possible to remove reagents-andkbyproducts by filtration, and thus recrystallization of { intermediates is unnecessary.ι , . . I .υ ί ι:ίίI ttThe protected amino acids can be linked to any suitable polymers, which merely have to be insoluble in the solvents used and to have a stable physical form which makes filtration easy. The polymer must contain a functional group to which the first protected amino acid can be firmly attached by a covalent bond. Suitable for this purpose are a wide variety of polymers, eg. cellulose, polyvinyl alcohol, polymethacrylate, sulfonated polystyrene, chloromethylated styrene / divinylbenzene copolymer (Merrifield resin), 4-methylbenzhydrylamine resin (MBHAresin), phenylacetamidomethyl-resin (Pam-resin), pbenzyloxy-benzyl-alcohol-resin, benzhydryl-amine-resin (BHA-resin), 4-(hydroxymethyl)-benzoyloxy-methyl-resin, the resin of Breipohl et al' (Tetrahedron Letters 28 ¢1987)65; supplied by BACHEM), 4 - (2,4-dimethoxyphenylaminomethyl)phenoxy-resin (supplied by Novabiochem) or o-chlorotrityl-resin (supplied by Biohellas).i.Suitable for peptide synthesis in solution are all solvents which are inert under tAe reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and· mixtures of the said solvents. Peptide synthesis on the polymeric support can be carried out in all inert organic solvents in which the amino-acid derivatives used are soluble. However, preferred solvents additionally have resin-swelling properties, such as DMF, DCM, NMP, acetonitrile and DMSO, and mixtures of these solvents.After synthesis is complete, the peptide is cleaved off the polymeric support. The Conditions under which cleavage off the various resin types ]is possible are disclosed in the literature. The cleavage reactions most commonly used are acid- and palladium-catalyzed, especially cleavage in liquid anhydrous hydrogen fluoride, in anhydrous trifluoromethanesulfonic acid, in dilute or concentrated trifluoroacetic acid, palladium-catalyzed cleavage in THF or THF-DCM mixtures in the presence of a weak base such as morpholine or cleavage in acetic acid-dichloromethanetrifluoroethanol mixtures. Depending on the chosen protective groups, these} may be retained or likewise cleaved off under the cleavage conditions. -- -- ----Partial deprotection of phe peptide may also be worthwhile when certain derivatization reactions are to be carried out. Peptides dialkylated at the N-terminus can be prepareda) by coupling of the appropriate N,N-di-alkylamino acids45' in solution or on the [polymeric support, b) bv reductive alkylation cf the resin-bound peptide in DMT / li acetic acid ι with NaCNBHj and the appropriate aldehyde or ketone, c) by , hydrogenation of the peptides in solution in the presence ' of aldehyde or ketone land Pd / C.> j(The various non-naturally occurring amino acids disclosed * herein may be obtained from commercial sources or , synthesized from commetcially-available materials using methods known in the art. Azetidine-2-carboxylic acid, ί 3-methyl-L-proline, 5-methyl-L-proline, and Boc- or Fmoc) protected 3, 4-dehydrop'roline are commercially available starting materials (ACROS, NOVABIOCHEM, BACHEM). Cis- and trans-4-fluoroproline can be prepared via a methodI described by Panasik et al. (N. Panasik, E.S. Eberhardt, ' A.S. Edison, D.R. Powell, R.T. Raines, Int. J. Peptide * Protein Res. 44, 1994,;262-269) from hydroxyproline.t The compounds of this invention may be used to inhibit or t otherwise treat solid tumors (e.g. tumors of the lung,kbreast, colon, prostate, bladder, rectum, or endometrial tumors) or hematological malignancies (e.g. leukemias, j lymphomas) by administration of the compound to the mammal, i !It is a special advantage of the new compounds that they i are more resistant to enzymatic degredation as compared to , Dolastatin-15. j ί Administration may be by any of the means which are t conventional for pharmaceutical, preferably oncological, i agents, including oral!and parenteral means such as t subcutaneously, intravenously, intramuscularly and [ intraperitoneally. j i The compounds may be administered alone or in the form of pharmaceutical compositions containing a compound of ! formula I together with a pharmaceutically accepted carrier ί appropriate for the desired route of administration. Such j pharmaceutical compositions may be combination products, | i.e., may also contain lother therapeutically active j ingredients. i ί The dosage to be administered to the mammal-will contain an j effective tumor-inhibiting amount of active ingredient j which will depend upon [conventional factors including the .biological activity of [the particular compound employed; :tΤ'tthe means of administration; the age, health and body | weight of the recipient; the nature and extent of the symptoms; the frequency of treatment; the administration of I other therapies; and the effect desired. A typical daily1dose will be about 0.5 to 50 milligrams per kilogram of , body weight on oral administration and about 0.05 to 20 onJ parenteral administration.The novel compounds can be administered in conventional 10 ‘ solid or liquid pharmaceutical administration forms, e.g.[ uncoated or (film-) coated tablets, capsules, powders, j granules, suppositories or solutions. These are produced in ι a conventional manner. The active substances can for this | purpose be processed with conventional pharmaceutical aids1 such as tablet binders,! fillers, preservatives, tablet i disintegrants, flow regulators, plasticizers, wetting ι agents, dispersants, eiriulsifiers, solvents, sustained ref lease compositions, antioxidants and / or propellant gases | (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme20 ϊ Verlag, Stuttgart, 1978!) , The administration forms obtained i in this way normally contain 1-90% by weight of the activeI substance. i i :i· . The following examples are intended to illustrate the(invention. The proteinogenous amino acids are abbreviated1in the examples using the known three-letter code. Other Ϊ abbreviations used: Me2Val=N,N-dimethylvaline, MeVal=N* methylvaline, Z=benzyloxycarbonyl.I ’ ! A. General procedures * • I- I. The peptides claimed;in claim 1 are either synthesized by classical solution synthesis using standard Z- and Boc( methodology as described above or by standard methods of ί solid-phase synthesis using Boc and Fmoc protective group techniques. , ’ II <a) Synthetic cycle for the Fmoc protective group technique40 > 1. ! 2· I t j 5. DMF washing ι 20% piperidine in DMF 20% piperidine in DMF DMF washing Addition of the preactivated 1 1 5 x 1 min x 4 min x 16 min x 1 min 45 protected'-amino' acid (activation by 1 equivalent of |TBTU andi equivalents of :DI?FA in DM?); Peptide coupling ' . DMF washing7. if conversion is incomplete, repetition of coupling (back to 5.8. DMF washing19. back to 2. ' x 51 min 3x1 min3x1 minΒΟΡ-Cl and PyBrop were used as reagents for coupling of the amino acid following the N-methylamino acids. The reaction times were correspondingly increased including double couplings. In solution synthesis, the use of either Bocprotected amino acid NCA's (N-carboxy anhydrides), Zprotected amino acid NCA's (N-carboxy anhydrides), or the use of pivaioylchloride as condensing agent respectively is most advantageous for;this type of coupling.II. Reductive alkylation of the N-terminus [t >The peptide-resin prepared as in Ala was deprotected at the N-terminus (steps 2-4: in Ala) and then reacted with a 3-fold molar excess of aldehyde or ketone in DMF / 1% acetic acid with addition of'3 equivalents of NaCNBH3. After· reaction was complete!(negative Kaiser test) the resin was washed several times with water, isopropanol, DMF and dichloromethane.Reductive alkylation in solution can e.g. be achieved by reaction of the N-terminally deprotected peptides, peptide fragments, or amino acids with the corresponding aldehydes or ketones using NaCNBH3or hydrogen-Pd / C.ίIII. Work-up of the pdptide-resins obtained as in lb and IIThe peptide-resin was; dried under reduced pressure and then subjected to treatment with a TFA / water mixture (95:5) for 1,5 hours (Wade, Tregear, Howard Florey Fmoc Workshop Manual, Melbourne 1985) . The resin was then filtered off and washed with TFA and DCM. The filtrate and the washings were concentrated, and the peptide was precipitated by addition of diethyl either. After cooling in an ice bath, the precipitate was filtered off, taken up in 30% acetic acid and lyophilized J iiIV. When an o-chlorotrityl-resin (supplied by Biohellas) is used,, the suspension !of the peptide-resin in an acetic ?acid / tr'ifluoroethanol / dichlorometKane mixture (Γ: 1:3) isΤ ’ST·-.·**’ · % ι stirred at room temperature for 1 h. The resin is then j filtered off with suction and thoroughly washed with the cleavage solution. Theicombined filtrates are concentrated in vacuo and treated with ether. The precipitated solid is1removed by filtration or centrifugation, washed with diethyl ether and dried under reduced pressure.l ' i V. Purification and characterization of the peptidesPurification was carried out by gel chromatography ί (SEPHADEX G-10, G- 15 / 1.0% HOAc, SEPHADEX LH20 / MeOH) and / or , medium pressure chromatography (stationary phase: HD-SIL C8, 20-45 mikron, 100 Aingstrom; mobile phase: gradient with A = 0.1% TFA / water, 3 0.1% TFA / MeOH), or preparative HPLC < (stationary phase: Waters Delta-Pak C-18, 15 mikron, 100 I Angstrom; mobile phasd: gradient with A = 0.1 % TFA / water, ί B = 0.1 % TFA / MeOH). j l· iThe purity of the resulting products was determined by f analytical HPLC (stationary phase: 100 2.1 mm VYDAC C-18, i 300 Angstrom; mobile phase: acetonitrile-water gradient, * buffered with 0.1% TFA, 40°C) .j Characterization was by fast atom bombardment mass spectroscopy and NMR spectroscopy.! . j , B. Specific proceduresI ,· EXAMPLE 1 (SEQ ID NO: 1) ( Me2Val-Val-MeVal-3,4-dehydroprolyl-Pro-amide ί :!|:0.53 g of Fmoc-RINK-resin (substitution 0.46 mmol / g), ’ corresponding to a batch size of 0.25 mmol, were reacted as in Ala with 0.4 mmol each of35: 'Fmoc-Pro-OHFmoc-3,4-dehydroproline Fmoc-MeVal-OH .Fmoc-Val-OH ί40, Fmoc-Val-OH t—The amino acid following;-the. N-methylamino acid was coupled i on with PyBrop as coupling reagent with a double coupling.* After the iterative synthetic cycles were completed, the peptide·· resin underwent N-terminal deprotection (steps 2-4 j in Ala)- / '‘and?was further reacted with aqueous formaldehyde ίF ί solution as in All and;then dried under reduced pressure., The resulting resin was subjected to TEA cleavage as in | AIII. The crude product (132 mg) was purified by preparative medium pressure chromatography to yield 32 mg 5 » of the desired pure peptide (10-40% A in 10'; 40-90% A in . 140'). The compound wa^ further characterized by fast atom < bombardment mass spectrometry ([M+H]+= 548).] ' EXAMPLE. 2 (SEQ ID NO:; 1) ji(Me2Val-Val-MeVal - [ ( 2S ,'3S) -3 - methyl-pyrrolidine - 2 - carbonyl ] Pro-benzylamide ri ' i a) Z-(2S,3S)-3-Methyl-pyrollidine-2-carboxylic acidI i 1.5 g (2S,3S)-3-Methyl-pyrrolidine-2-carboxylic acid ¢11.6 mmol) were dissolved in 4 ml water and 2.33 ml 5 N NaOH. At ί 4°C, 2.12 ml benzylchloroformate (Z-Cl; 12.8 mmol) and 6.5 20 c ml 2 N NaOH were added within 1 h. After the reaction (· mixture was stirred overnight at room temperature, the pH was adjusted to 10. The aqueous layer was extracted with dichloromethane (4x)adjusted to pH 2 with 5 N HCI and > extracted with dichloromethane (2x). The combined organic 25'textracts were dried over sodium sulfate and evaporated in vacuo to yield 1.75 gi of the desired product as an oil. f !b) Z-(2S,3S)-3-Methyl-pyrrolidine-2-carbonyl-L-prolyl ) benzylamide < I ‘ · 1.75 g (2S,3S)-3-Methyl-pyrrolidine-2-carboxylic acidJ (6.62 mmol) and 1.59 g proline benzylamide hydrochloridet¢6.62 mmol) were dissolved in 66 ml dichloromethane and cooled to 4°C. After addition of 0.89 ml N-methylmorpholine 35· ¢7.94 mmol), 0.304 g !HOBt (2.21 mmol) and 1.28 g EDCI ¢6.62 mmol), the reaction mixture was stirred at room temperature f overnight, diluted with 150 ml dichloromethane, and washedLwith saturated sodium hydrogen carbonate solution (3x), ί water (lx), 5 % citric acid (3x), water (lx), and saturatedNaCl (lx). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to yield 2.63 g of ’ j” ' ‘ a highly viscous oil . -----I | (f ' iΙ:'I ιc) (2S,3S) - 3 -Met hyl -^pyrrolidine- 2 - carbonyl-L-prolyl benzylamideI :I* 2.63 g Z - ( 2S, 3 S) - 3 - Methyl-pyrrolidine - 2 -carbonyl-L-prolyl 5 benzylamide (5.3 mmol) were dissolved in 43 ml methanol.b After addition of 105 ;mg 10 % Palladium / charcoal, the j reaction mixture was hydrogenated overnight. Filtration and ' evaporation to dryness yielded 1.88 g of the deprotected * dipeptide10.d) Z-MeVal-[(2S,3S) - 3-Methyl-pyrrolidine-2 - carbonyl]-Proi benzylamide f 1.54 Z-MeVal-OH ¢5.8 mmol) and 1.88 g (2S,3S)-3-Methyl15 pyrrolidine-2-carbonyl-L-prolyl benzylamide (5.8 mmol) were I dissolved in 58 ml dichloromethane and cooled to 4°C. After addition of 0.78 ml N-methylmorpholine (6.96 mmol), 0.266 g j' HOBt (1.93 mmol) and 1.12 g EDCI (5.8 mmol), the reaction f mixture was stirred at room temperature overnight, diluted with 120 ml dichloromethane, and washed with sat. sodium ! hydrogen carbonate, once (3x), water (lx), 5 % citric acid * (3x), water (lx), and; sat. NaCI (lx). The organic layer was ’ dried over sodium sulfate and concentrated under reduced pressure to yield 3.01 g of the product as a dry white foam. ;‘ e) MeVal-[(2S,3S)-3'-Methyl-pyrrolidine-2-carbonyl]-Probenzylamidei.3.01 g of Z-MeVal-[(2S,3S)-3-Methyl-pyrrolidine-2carbonyl]-Pro-benzylamide (5.33 mmol) were dissolved in 39I ml methanol. After addition of 96 mg 10 % f Palladium / charcoal, the reaction mixture was hydrogenated for 3 h. Filtration and evaporation to dryness yielded 2.18kg of the deprotected tripeptide as a clear oil.If) Z-Val-MeVal - [ (2S,3S)-3-Methyl-pyrrolidine-2-carbonyl]ί Pro-benzylamide40* 1.28 g Z-Val-OH <5.11* mmol) were dissolved in 10 ml j dichloromethane. After addition of 0.73 ml triethylamine-·-> - .-(.5 . -37-mmol-) - and cooling to -10oC,-Ov66 -ml pivaloylchloride ί (5.37 mmol) were added slowly. Stirring of the mixture at j / -1O°C for 1.5 h was followed by addition of a solution-of ‘ 2,18 ,J3 MeVal: [ ( 2S, 3S),-3-Methyl-pyrrolidine-2- carbonyl ] - Pro i- benzylamide (5.11 mmol) and 0.73 ml triethylamine· (5.37I ί ί ιt l· ιr ,Of / i.r- .mmol) in 10 ml dichloromethane. The reaction mixture was stirred at -10°C for 1.5 h and at room temperature overnight, diluted with dichloromethane, and washed with sat. sodium hydrogen carbonate (3x), water (lx), 5 % citric acid (3x), water (lx), 'and sat. NaCl (lx). The organic layer was dried over sodium sulfate and concentrated in vacuo to yield 2.75 g of the product as a dry foam.g) Val-MeVal-[(2S,3S)- 3-Methyl-pyrrolidine-2-carbonyl]Pro-benzylamide2.75 g of Ζ-Val-MeVal-[(2S,3S)- 3-Methyl-pyrrolidine - 2 carbonyl] - Pro-benzylamide (4.13 mmol) were dissolved in 30 ml methanol. After addition of 0.34 ml cone. HCI (4.13 mmol) and 78 mg 10 % Palladium / charcoal, the reaction mixture was hydrogenated for 3 h. Filtration and evaporation to dryness yielded 2.23 g of the deprotected tripeptide as a dry white foam. The crude product was further dissolved in 50 ml water and the pH adjusted to 2-3 with 1 N HCI. The aqueous layer was extracted with dichloromethane (3x), ’adjusted to pH 10 with 5 N NaOH, and' further extracted with dichloromethane (3x). The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure to yield 1.71 g of the deprotected tetrapeptide benzylamide.h) Me2Val-Val-MeVal-[(2S,3S)-3-Methyl-pyrrolidine-2carbonyl]-Pro-benzylamide0.47 g Me2Val-OH (3.24 mmol) and 1.71 g Val-MeVal-((2S,3S) 3-Methyl-pyrrolidine-2-carbonyl]-Pro-benzylamide (3.24 mmol) were dissolved in 32 ml dry DMF. After cooling to 4°C, 1.07 ml DEPCN (6.48 mmol) and 1.83 ml triethylamine ¢12.96 mmol) were added. The reaction mixture was stirred at room temperature overnight and the DMF evaporated under reduced pressure. The residue was dissolved in 100 ml dichloromethane and washed with sat. sodium hydrogen carbonate (3x), water (lx), 5 % citric acid (3x), water (lx), and sat. NaCl (lx). The organic layer was dried over sodium sulfate.and concentrated under reduced pressure to yield 0.88 g of the product as a colourless oil. The crude 'product was dissolved in boiling'diisopropylether and precipitated upon cooling. The precipitate was collected and dried to yield 0^56 g of the pure product. The compound was further characterized . by fast atom bombardment mass spectrometry ( [M+H] * '= -65 5 / 6) .The following compounds were prepared and can be prepared r according to examples '1 and 2:λ3 . Xaa Val Xab Xac Xad 5 4 . Xaa Val Xab Xac Xae f 5. Xaa Val Xab Xac Xaf 6. Xaa Val Xab Xac Xag 7 . Xaa Val Xab Xac Xah 8 . Xaa Val Xab Xac Xai l LO 9. Xaa Val Xab Xac Xak 10. Xaa Val Xab Xac Xal 11. Xaa Val Xab Xac Xam 12. Xaa Val Xab Xac Xan 13. Xaa Val Xab Xac Xao 15 ί 14. Xaa Val Xab Xac Xap 15. Xaa Val Xab Xac Xaq v 16. Xaa Val Xab Xac Xar F 17. Xaa Val Xab Xac Xas 18. Xaa Val Xab Xac Xat 20 ! 19. Xaa Val Xab Xac Xat ]- ) 20. Xaa Val Xab Xac Xav 21. Xaa Val Xab Xac Xaw 22. Xaa Val Xab Xac Xax I 23. Xaa Val Xab Xac Xay 25 ' 24 . Xaa Val Xab Xac Xaz 25. Xaa Val Xab Xac Xba 1 26. Xaa Val Xab Xac Xbb 1 27. Xaa Val Xab Xac Xbc f 28. Xaa Val Xab Xac Xbd 30j 29. Xaa Val Xab Xac Xbe 1 30. Xaa Val Xab Xac Xbf 1 31. Xbg Val Xab Xac Xar 32. Xbg Val Xab Xac Xas r 33. Xbh Val Xab Xac Xar 35 [ 34. Xbh Val Xab Xac Xas J 1 35. Xaa Ile Xab Xac Xar 36. Xaa Ile Xab Xac Xas 1 ]: 37. Xaa Xbk Xab Xac I Xar k I 38. Xaa Xbk Xab Xac Xas 40 f 39. Xaa Val Xbi Xac Xar 1 40. Xaa Val Xbi Xac ϊ Xas ‘1 41. Xaa Val Xab Xac Xbi 1 t k 42. Xaa Val Xab Xac , Xbm 43.· Xaa Val Xab Xac Xbn 45?. .: ; .4 4.,- Xaa Val Xab Xbo Xae 1 J ·’ 45. Xaa Val Xab Xbo. Xbpί· trl· 1 f 4 6 . 47. 48. 49. Xaa val Xaa Val Xaa Val Xaa Val Xab Xbo Xar Xab Xbo Xas Xab Xbo Xbm Xab Xbq Xae 5 ί 50. Xaa Val Xab Xbq Xar i 51. Xaa Val Xab Xbq Xas 52. Xaa val Xab Xbq Xbm r 53. Xaa Val Xab Xbr Xbp ί 54. Xaa Val Xab Xbr Xae 10 ' 55. Xaa Val Xab Xbr Xas 'li- 56 . Xaa Val Xab Xbr Xar [ 57 . Xaa Val Xab Xbs Xae r- 58 . Xaa Val Xab Xbs Xas Γ 59. Xaa Val Xab Xbs Xar j 15 ί 60 . Xaa Val Xab Xac Xbu f 61. Xaa Val Xab Xac Xbt 1 62. Xaa Val Xab Xbq Xbu 63 . Xaa Val Xab Xbq Xbt 64. Xaa Val Xab Xac Pro Xbv 20 ί 65. Xaa Val Xab Xac Pro Xbw P j 66. Xaa Val Xab Xac Pro Xbx i. l· 67. Xaa Val Xab Xac Pro Xby It 68. Xaa Val Xab Xac Pro Xbz 64. Xaa Val Xab Xbq Pro Xbv 25 .· 65. Xaa Val Xab Xbq jpro Xbw 66. Xaa Val Xab Xbq Pro Xbx I 67 . Xaa Val Xab Xbq ;Pro Xby 68. Xaa Val Xab Xbq Pro Xbz 69. Xaa Val Xab Xbo Xaz 30 : 70. Xaa Val Xab Xbq Xaz r. 71. Xaa Val Xab Xbq Xbn ι 1 72. Xaa Val Xab Xbo: ' Xbn 35 i f Examples for the MS-characterization of the synthesized ί novel compounds are given in the following table. 1 EXAMPLE atom bombardment MS analysis. 40 t [No. ] [Mol.-Weight (measured)] ί 45. 627 1 I 53. . . -, μ '655-' ' - ·Table I - Sequence Identification of Compounds PreparedAccording to Examples 1 and 2 iCompound Number(s) Sequence TD Number ; 1-34, 39-63, 69-72 1 ί 35, 36 2 »37, 38 3I i 64-68 j 4I ίr ioThe symbolsXaa:Xab:Xac :Xaa in the summary have the following meaningsN,N-Dimethylvaline N-MetKylvaline jXad:f !Xae:<*3 ch3Xafι.fXag:ί tjiII ’Xah:lXai :Xak:Xal:t iXamPSfXan:ί r10ίXao:k- Ϊ Xap:rF il· kXaq:l·F iίI tΪI, / ΛXarXast ' Xbf;ιΙΟ hίXbg:Xbh:Xbi:Xbk:N,N-dimethylisoleucineN,N-dimethyl-2-tert.butyl-glycine N-methylisoleucine2-tert.butylglycineXbl:t tt hV l·Xbm:Xbn:Xbo:o / “-γΝγΟί, Ο Κ,ΟL-azetidine-2-carbonylIί Xbp *hXbqXbrXbs ί(4-fluoro)-L-proline (5-methyl)-L-proline (3-methyl)-L-proline ' XbtOHOXbuIP ,i iί fXbvXbw nt ιfrk.* Xbx:I h3cvch3xnAYN^CH:CHΗ3%>xnAYN'^'CHCH ίXbz-n-Rn^chH„C0I, ii . ΓCompounds of this invention may be assayed for anti-cancer activity by conventional methods, including for example, the methods described below.A. In vitro methodology j Cytotoxicity was measured using a standard methodology for adherent cell lines such as the microculture tetrazolium ) assay (MTT). Details of this assay have been publishedt' (Alley, MC et al, Cancer Research 48:589-601, 1988).< Exponentially growing cultures of tumor cells such as theJ HT-29 colon carcinoma or LX-1 lung tumor are used to make microtiter plate cultures. Cells are seeded at 5000-20,000 cells per well in 96-well plates (in 150 jil of media), and j grown overnight at 37°C. Test compounds are added, in 10-fold dilutions varying from 10'4M to 10_io M. Cells ' are then incubated for 48 hours. To determine the number of viable cells in each well, the MTT dye is added (50 Jil of 3 mg / ml solution of 3 - (4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide in saline). This mixture is incubated at 37OC for 5 hours, and then 50 μΐ of 25 % SDS,J pH2 is added to each well. After an overnight incubation, the absorbance of each well at 550 nm is read using anELISA reader. The values for the mean + / -SD of data from replicated wells are calculated, using the formula % T / C (% viable cells treated / control).ί·OD of treated cells.............-..... x 100 » % T / COD of control cellsThe concentration of test compound which gives a T / C of 50% growth inhibition was designated as the ICso value.COMPOUND OF EXAMPLE ΓΜ1 1. 1 x 10-9 2. 1 x 10-9 45. 1 X 10-9 53. 1 X 10-83. In vivo methodology *Compounds of this invention were further tested in prerclinical assay for in vivo activity which is indicative of clinical utility. Such assays were conducted with nude mice into which tumor tissue, preferably of human origin, had been transplanted (xenografted), as is well known in this •j field. Test compounds were evaluated for their anti-tumor '' efficacy following administration to the xenograft-bearing mice.IMore . specifically, human breast tumors (MX-1) which had been grown in athymic nude mice were transplanted into new recipient mice, using tumor fragments which were about 50 mg in size. The day. of transplantation was designated as < day 0. Six to ten days later, mice were treated with the , test compounds given as an intravenous injection, in groups * of 5-10 mice at each dose. Compounds were given every otherJ day, for 3 weeks, at doses from 1-100 mg / kg body weight.Tumor diameters and body weights were measured twice j: weekly. Tumor volumes were calculated using the diameters , measured with Vernier calipers, and the formula (length x width2) / 2 = mm3 of tumor volumeMean tumor volumes are calculated for each treatment group, ί and T / C values determined for each group relative to the ! untreated control tumors.ΪThe new compounds possess good tumor inhibiting properties.i kf ίr thSEQUENCE LISTING (1) GENERAL INFORMATIONr' I (i) APPLICANT:- 5 ' ( G r (A) 3ASF Aktiengesellschaft (B) STREET: Carl-3osch-Strasse 38 (C) CITY: Ludwigshafen (E) COUNTRY: Bundesrepublik Deutschland (F) ZIP: D-67056 10 1 1·· 1 (G) TELEPHONE: 0621 / 6048526 (H) TELEFAX: 0621 / 6043123 (I) TELEX: 1762175170(ii) TITLE OF INVENTION: Novel peptides, the 15 preparation and use thereof ! (iii)NUMBER OF SEQUENCES: 4 ί(iv) COMPUTER READABLE FORM:(A) MEDIUM TYPE: Diskette, 3,5 inch, 2 DD (B) COMPUTER: IBM AT-compatible, 80286 processor (C) OPERATING SYSTEM: MS-DOS version 5.0 (D) SOFTWARE: WordPerfect25;.r r]r?(2) INFORMATION FOR SEQ ID NO: 1:(i) SEQUENCE CHARACTERISTICS :(A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:Xaa Val Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 2:J (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 5 amino acids1(B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide i (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:Ϊ Xaa He Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 3:(i) SEQUENCE CEARACTERISTICS (A) LENGTH: 5 amino acids(> (3) TYPE: amino acid4 (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:*Xaa Xaa Xaa Xaa Xaa fj (2) INFORMATION FOR SEQ ID NO: 4:(i) SEQUENCE CHARACTERISTICS :' (A) LENGTH: 6 amino acids (B) TYPE: amino acidI (D) TOPOLOGY: linear r (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: 20*:Xaa Val Xaa Xaa Pro Xaa
Claims
CLAIMS :
1. Peptides of the formula I R^N-CHX-CO-A-B-D-E- (F) t-K where 10 R1 is methyl, ethyl, or isopropyl; R2 is hydrogen, methyl, or ethyl; R--N-R2 together may be a pyrrollidine ring; A is a valyl, isoleucyl, leucy, 2-tert-butylglycyl,2-ethylglycyl, norleucyl or norvalyl residue; B is a N-methyl-valyl, -leucyl, -isoleucy, 20 norvalyl, -norleucyl -2-tert-butylglycyl, -3-tertfc butylalanyl, or-2-ethylglycyl residue; D is a 3,4-dehydroprolyl, 4-fluoroprolyl, 4-4difluoroprolyl, azetidine-2-carbonyl, 325 methylprolyl, 4-methylprolyl, or 5-methylprolyl Τ' j residue; l·· J E is a proplyl, homoprolyl, hydroxyprolyl or ; thiazolidine-4-carbonyl residue; F is a valyl, 2-tert-butylglycyl, isoleucyl, leucyl, Ϊ 2-cyclohexylglycyl,norleucyl, norvalyl, , neopenty1glycyl, alanyl, β-alany1, or h1 aminoisobutyroyl residue; ι X is alkyl (preferably C2.5) , cyclopropyl, or cyclopentyl·; t t K f 15 f i. is 0 or 1; and C1_4-al koxy, benzyloxy1, -NH2, or a substituted amino moiety which is -NH-C^-^-alkyl, -NH-C (CH3) 2CN, -NH-C (Ch3) 2CCH, -NHC (CH3) 2C=CH2, -NH-C <CH3) 2CH2CH2OH, -NH-C (CH3) 2CH2OH, NH-C3.e-cycloslkyl,-NH-[3,3,0]-bicyclooctyl, norephedryl, norpseudoephedryl, -NH-quinolyl, -NHpyrazyl, -NH-CH2-benz imidazolyl, -NH-adamantyl, NH-CH2-adamantyl, -NH-CH (CH3) -phenyl, -NH-C (CH3> 2phenyl, -N (C1_4-alkoxy)-C1_4-aikyl, ~N (Cj^-alkoxy) CH2-phenyl, -N (C1_i-alkoxyl}-phenyl, -N(CH3)OBzl, NH - (CH2) v-phenyl (v=0, 1,2, or 3} , -NH- (CH2) ^-naphthyl (m=0 or 1), -NH-(CH2) „-benzhydryl (w=0,l, or 2), NH-biphenyl, -NH-pyridyl, -NH-CH2-pyr idyl, -NH-CH2CH2-pyridyl, -NH-benzothiazolyl, -NHbenzoisothia zolyl, -NH-benzopyrazolyl, -NHbenzoxazolyl, -NH-(CH2) m-fluorenyl (m=0orl), -NHpyrimidyl, -NH- (CH2)m-indanyl (m=0 or 1), -NH(CH2CH2O) y-CH3 (y=0,1,2,3,4, or 5), -NH- (CH2CH2O) yCH2CH3 (y=0,l,2,3,4,or5),-(CH2CHzO)y-CH3 (y=0,1,2,3,4, or 5), - (CH2CH2O) y-CH2CH3 (y=0,1,2,3,4,5, or 5), -NCH3-NH-C6H5, -NCH3-NH-CH2CH2-C6H3; or K is F κ l·, I t r f30 and the salts thereof with physiologically tolerated acids. I 2. The compounds of claim 1, where i ! Rl j 35 R2 is methyl or ethyl; is hydrogen, methyl, or ethyl; A is valyl, isoleucyl, 2-tert-butylglycyl residue; B is a N-methyl-valyl, -isoleucyl, or 2-tert-butylglycyl residue; D is a 3,4-dehydroprolyl, 4-fluoroprolyl, azetidine-2carbonyl, 3-methylprolyl, or 5-methyl-prolyl residue; E is a proplyl, homoprolyl, hydroxyprolyl or I 10 thiazolidine-4-carbonyl residue; j F is a D-valyl, 2-tert-butylglycyl, D-isoleucyl, Dleucyl, or aminoisobutyroyl residue; 15 x is-CH(CH3)2, -C(CH3)3, or -CH (CH3) CH2CH3; t is 0 or 1. i 1 3. The compounds of claim 1 or claim 2, where K is 20 -OC(CK3)3, -NHCH3, -NHCH2CH3, -NH (CH2)2CH3, -NH (CH2) 3CH3, J. f NH (CH2) <CH3, -NH (CH2) 5CH3, -NH <CH2) 6CH3, -NH (CH2) 7CH3, -NHCH (CH3) 2, ‘ NHCH (CH3)CH2CH3, - NHCH (CH3)CH2CH2CH3, - NHCH ( C H 2 C H 3 ) 2 , ; NH(CH2CH2CH3)2, - NHC (CH3)3, - NHCH (CH2CH3)CH2CH2CH3, ' NHCH(CH3)CH(CH3)2, -NHCH (CH2CH3) CH (CH3}2, -NHCH (CH3) C (CH3) 3, 25 NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH1' cyclohexyl, -NH-cycloheptyl, -NH-cycloc t yl, -NHj. bicyclo [3,3, 0] octyl, -N (CH3) OCH3, -N (CH3) OCH2CH3, ’ M (CH3) OCH2CH2CH3, -ν (CH3) OCH (CH3) 2, -N (CH2CH3) OCH3, j N (CH2CH3)OCH2H3, -N(CH(CH3)2)OCH3, -N(CH3)OCH2C6H5, -N(OCH3) ch230 C6H5, -N (CH3) OC6H5, -NH-CH2C6H5, -NH (CH2) 2C6H5, -NH (CH2)3C6H5, r NHCH (CH3) c6h5, -NHC (CH3) 2C6H5, -NHC (CH3) 2ch2ch3, ) NCH (CH3) (CH2CH3)2, -NHCH (CH3) CH (OH) C6H5, -NHCH2-cyclohexyl, -ΝΗί CH2CF3, -NHCH (CH2F) 2, -NCH (CH3) 2CH2CH2OH, -NH (CH2CH2O) 2CH2CH3, NHC (CH3) 2CH (CH (CH3) 2, -NHC (CH3) 2CN, -NHC (CH3) 2CCH, norephedryl, 35 norpseudoephedryl, -NH-quinolyl, -NH-pyrazyl, -NH41 adamantyl(2), -NH-adamantyl (1) , -NH-CH;-adamantyl, -NH-CH2J naphtyl, -NH-benzhydryl, -NH-biphenyl,-NH-pyridyl,-NH-CH2pyridyl, -NH-CH2-CH2-pyridyl, -NH-benzothiazolyl, -NHbenzoisothiazoly, -NH-benzopyrazoly, -NH-benzoxazoly, -NH5 fluorenyl, -NH-pyrimidyl, -NH-CH2-(4-methyl)-thizolyl (2), F NH-CH,-furanyl(2), -NH-CH2-thienyl(2), -NH-CH2-(5methyl}thienyl(2), -NH-thiazoly(2) , -NH-soxazolyl(3), -NH( (3-methyl)isoxazolyl(5 ) , -NH-(3-methyl)isothiazolyl(5) , -NHr= (2-trifluormethyl)-thiadiazoly(5), - N H - ( 2 10 cyclopropyl)thiadiazoly(5), -NHC(CH3) 2C=CH2, or K may be N\_J Γ\ *N 0 H.C H,C O -O -o —» O -¾ -¾ f t' j 4. The compounds of any of claims 1 to 3 for use in fc medicine in particular for treating oncological diseases. t l· 25 5. A pharmaceutical composition comprising a > pharmaceutically acceptable carrier and a therapeutically ( effective amount of a compound of any of claims 1 to 3. F £ 6. Use of a compound of any of claim 1 to 3 for preparing 30 a pharmaceutical composition for treating a tumor in a mamma 1. .... i :
7. A method for preparing compounds of any of claims 1 to3, characterized in that they are prepared according to 35 known methods of peptide chemistry.
